Scorpius Biomanufacturing
Scorpius BioManufacturing is a U.S. biologics CDMO providing cGMP manufacturing, bioanalytical, and process development services for protein modalities. Located in San Antonio, Texas, it specializes in working with emerging biotechs, academic researchers, and U.S. Government institutions. The company emphasizes quality, speed, flexibility, and responsiveness, with capabilities including mammalian and microbial biomanufacturing, analytical services, and a commitment to American-made equipment and consumables. It aims to be a leading CDMO for emerging biotech innovators, supporting the development of safe, high-quality therapies through lifelong partnerships.
Industries
Nr. of Employees
medium (51-250)
Scorpius Biomanufacturing
San Antonio, Texas, United States, North America
Products
CMC Analytical
Comprehensive range of analytical testing services for the characterization of complex biologics, vaccines, and advanced therapies, including cGMP lot release testing and analytical method development.
CMC Analytical Support
Chemistry, Manufacturing, and Controls (CMC) analytical support for biologics and large molecule projects.
ELISA
Enzyme-linked immunosorbent assay services provided for quantitative, semiquantitative, or qualitative detection of various analytes.
ELISA (Enzyme-linked Immunosorbent Assays)
Enzyme-linked immunosorbent assays (ELISA) are the most common method for ligand binding assays and are a core competency at Scorpius, providing a fast, reliable, and cost-effective platform for analyte quantification in biologics and cell and gene therapies.
Immunooncology Checkpoint 14-Plex Human Panel 1
Predefined human multiplex panel targeting immunooncology checkpoint proteins such as BTLA, CD80, CTLA4, PD-1, and PD-L1.
Immunooncology Checkpoint 14-Plex Human Panel 2
Predefined human multiplex panel targeting alternative immunooncology checkpoint markers and ligands like Arginase-1, CD73, and E-Cadherin.
CMC Analytical
Comprehensive range of analytical testing services for the characterization of complex biologics, vaccines, and advanced therapies, including cGMP lot release testing and analytical method development.
CMC Analytical Support
Chemistry, Manufacturing, and Controls (CMC) analytical support for biologics and large molecule projects.
ELISA
Enzyme-linked immunosorbent assay services provided for quantitative, semiquantitative, or qualitative detection of various analytes.
ELISA (Enzyme-linked Immunosorbent Assays)
Enzyme-linked immunosorbent assays (ELISA) are the most common method for ligand binding assays and are a core competency at Scorpius, providing a fast, reliable, and cost-effective platform for analyte quantification in biologics and cell and gene therapies.
Immunooncology Checkpoint 14-Plex Human Panel 1
Predefined human multiplex panel targeting immunooncology checkpoint proteins such as BTLA, CD80, CTLA4, PD-1, and PD-L1.
Immunooncology Checkpoint 14-Plex Human Panel 2
Predefined human multiplex panel targeting alternative immunooncology checkpoint markers and ligands like Arginase-1, CD73, and E-Cadherin.
Services
End-to-end biologics manufacturing services including upstream, downstream, formulation, and aseptic fill–finish in cGMP cleanrooms for mammalian, microbial, and cell therapy products.
Process development for mammalian and microbial platforms including scale-down modeling, optimization of culture and fermentation conditions, and downstream purification/refolding.
Analytical testing and bioanalysis covering preclinical and clinical phases, GLP-compliant sample analysis, and CMC analytical support for regulatory filings.
Design, optimization, and regulatory-aligned validation of cell-based assays, immunoassays, and molecular assays (qPCR), including multiplexed and automated formats.
Method development, qualification, and validation for CMC and characterization techniques (HPLC, SPR, microscopy) and stability testing programs.
Advisory and hands-on support to execute sponsor-to-manufacturer tech transfers and reduce manufacturing start-up risks.
End-to-end biologics manufacturing services including upstream, downstream, formulation, and aseptic fill–finish in cGMP cleanrooms for mammalian, microbial, and cell therapy products.
Process development for mammalian and microbial platforms including scale-down modeling, optimization of culture and fermentation conditions, and downstream purification/refolding.
Analytical testing and bioanalysis covering preclinical and clinical phases, GLP-compliant sample analysis, and CMC analytical support for regulatory filings.
Design, optimization, and regulatory-aligned validation of cell-based assays, immunoassays, and molecular assays (qPCR), including multiplexed and automated formats.
Method development, qualification, and validation for CMC and characterization techniques (HPLC, SPR, microscopy) and stability testing programs.
Advisory and hands-on support to execute sponsor-to-manufacturer tech transfers and reduce manufacturing start-up risks.
Expertise Areas
- Clinical biomanufacturing
- Mammalian cell culture and cell therapy manufacturing
- Microbial fermentation development
- Upstream and downstream process development
Key Technologies
- Single-use bioreactors
- Stainless steel bioreactors
- Hybrid single-use/stainless production platforms
- Miniaturized/scale-down bioreactor systems
News & Updates
Scorpius announces the launch of Scorpius Ventures, a new business unit designed to support emerging biotech companies with a flexible American onshoring model.
Scorpius has been selected to join the Medical CBRN Defense Consortium to advance medical countermeasures against chemical, biological, radiological, and nuclear threats.
NightHawk Biosciences announced its name change to Scorpius Holdings, Inc., reflecting its shift into a large molecule biomanufacturing CDMO.
Joe Payne has been promoted to President and COO of Scorpius BioManufacturing.
Capacity, capacity, capacity. This article discusses the need for biologics manufacturing capacity and how Scorpius supports emerging biotechs.
Joe Payne, President & COO of Scorpius, shares insights on creating a culture of quality in biomanufacturing.
Scorpius announces the launch of Scorpius Ventures, a new business unit designed to support emerging biotech companies with a flexible American onshoring model.
Scorpius has been selected to join the Medical CBRN Defense Consortium to advance medical countermeasures against chemical, biological, radiological, and nuclear threats.
NightHawk Biosciences announced its name change to Scorpius Holdings, Inc., reflecting its shift into a large molecule biomanufacturing CDMO.
Joe Payne has been promoted to President and COO of Scorpius BioManufacturing.
Capacity, capacity, capacity. This article discusses the need for biologics manufacturing capacity and how Scorpius supports emerging biotechs.
Joe Payne, President & COO of Scorpius, shares insights on creating a culture of quality in biomanufacturing.